Center for U.S. Policy

Advancing evenhanded solutions to our nation's challenges. Focusing heavily on substance use disorders and the drug poisoning crisis. 501(c)(3).

[Center for U.S. Policy @USPolicyCenter]

We are honored to welcome new board members @LaTonyaCLC, @MarshaPhDRN, and Ronne Ostby. Their leadership will bolster our efforts to promote evenhanded responses to the #substanceusedisorder, drug poisoning, and #mentalhealth crises.
https://t.co/3r6QAgsp9B

[Center for U.S. Policy @USPolicyCenter]

Last week, the FDA approved the first new pain reliever in 20+ years. This non-opioid targets sodium channels to treat acute pain. While trials showed its effectiveness in post-surgical patients, its benefits for chronic pain may be limited. Learn more: https://t.co/SKY3NxOtDj

[Center for U.S. Policy @USPolicyCenter]

Tomorrow, our Chairman @MCBtweets will moderate a Congressional briefing on enhancing decision-making and patient outcomes with AI, featuring policymakers, physicians, tech innovators, and patient care advocates. RSVP here: https://t.co/MOugaVwUFM

[Center for U.S. Policy @USPolicyCenter]

In response to an activist group opposing FDA funding for a substance misuse surveillance program, CUSP sent FDA a letter underscoring RADARS System's role in researching and responding to medication diversion, substance misuse, and addiction. Read letter: https://t.co/sP1X7qJEp4

[Center for U.S. Policy @USPolicyCenter]

Thank you @GovKathyHochul for signing S2677/A463 to help ensure patients get the information they need when faced with a denial due to #steptherapy. Thank you @NeilBreslin46 and @johnmcdonald108 for your leadership! #HappyHolidays

[Center for U.S. Policy @USPolicyCenter]

The Journal of Opioid Management has published a special edition, edited by our Chairman @MCBtweets and featuring our Senior Fellow @LynnRWebsterMD. It explores legal and policy responses to improper #pain management and #opioid misuse. Learn more: https://t.co/eWu9PDFnIV

[Center for U.S. Policy @USPolicyCenter]

Considering a career in addiction policy? Tune into the virtual info session on the M.S. in Addiction Policy and Practice program at Georgetown University's Graduate School of Arts & Sciences on Sept. 25 at noon hosted by @ReginaLabelle. Register here: https://t.co/n13uPKAQmu

[Center for U.S. Policy @USPolicyCenter]

.@InHealthPolicy reported FDA’s denial of CUSP’s Citizen Petition to classify risk assessment software a misbranded medical device and enforce a recall. Procedural grounds cited, but FDA will evaluate the matter for potential further actions. Learn more: https://t.co/uyGBp417Nu

[Center for U.S. Policy @USPolicyCenter]

On July 28, 2023, @US_FDA approved the second OTC #naloxone product, helping increase consumer access to naloxone without a prescription. It is anticipated to be available early 2024 to #harmreduction organizations and state governments. Learn more here: https://t.co/nmRynQzqKH

[Center for U.S. Policy @USPolicyCenter]

The @US_FDA denied the Citizen Petition by CUSP to deem a #SUD risk-scoring clinical decision support software a misbranded medical device. Despite the decision being procedural, the health and safety concerns raised remain significant. Learn more here: https://t.co/nzjgj8Z5lD

[Center for U.S. Policy @USPolicyCenter]

Thanks, @axios, for covering our citizen petition to protect people with #pain and others who need controlled medications. We appreciate your objectivity.

[Axios @axios]

An effort to get the FDA to pull a widely used prescription drug monitoring software package off the market is stoking a broader debate over how much technology is influencing opioid prescribing.

https://t.co/acpcoaxOzu

[Center for U.S. Policy @USPolicyCenter]

A more direct, efficient approach to enhancing access to #methadone for #OUD is to reduce regulatory burdens and delays hindering the establishment of OTP medication units in pharmacies. https://t.co/CR7KB67r5e

[Center for U.S. Policy @USPolicyCenter]

@mguptaphd @aander1987 @jenndoliva Given a lack of transparency as to which programs are used in health care, which data they analyze, and how they analyze it, we do not know.

[TwistedKat ♿️ @KatTwisted]

👏🏼👏🏼👏🏼👏🏼

[FanClub @HatingLiars]

Excellent News! This is a very good thing.

[Pain News Network @PainNewsNetwork]

A citizen's petition to #FDA asks that #NarxCare be taken off the market. #NarxCare software analyzes drug data to give patients “risk scores,” but critics say its a misbranded medical device that harms patients. @BambooHLTH #cpp #opioids #chronicpain https://t.co/7Ga71mYV5G

[Michael C. Barnes @MCBtweets]

When patients have inadequate access to medically necessary controlled medications, the harms can include relegation to the illicit drug market, exposure to substances adulterated with illegal fentanyl, prosecution and incarceration, drug poisoning, suicide, and death.

[Center for U.S. Policy @USPolicyCenter]

Thank you for your courageous thought leadership and advocacy, @jenndoliva. 🙏

[Center for U.S. Policy @USPolicyCenter]

Today, we filed a Citizen Petition asking @US_FDA to deem software that creates patient “risk scores” a misbranded device and to take action to prevent serious, adverse health consequences and death. Read the petition here: https://t.co/PQNkGYfBQf #OUD #pain #anxiety #insomnia

[Journal of Medical Regulation @JournalofMedReg]

JMR is extending an open call for submissions in 2023! We welcome manuscripts spanning original research, best practices, commentaries about patient safety & related matters relevant to medical regulators in the U.S. & around the world. https://t.co/hqi2ZDP6OU #callforpapers

[Journal of Medical Regulation @JournalofMedReg]

ICYMI: “Demanding Better: A Case for Increased Funding & Involvement of State Medical Boards in Response to America’s Drug Abuse Crisis,” by authors from @dcbalaw & @USPolicyCenter: https://t.co/L5MQmrt4wD